ALNY Live signals | Maximize Profits with Getagraph.com

BUY 1073 min ago

@ $146.36

Issued: 22 Apr 2024 @ 15:23

Return: -0.39%

Previous signal: Apr 19 - 15:19

Previous signal: Sell

Return: 1.28 %

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference...

Stats
Today's Volume	393 642
Average Volume	851 009
Market Cap	18.44B
EPS	$0 ( 2024-02-15 )
Next earnings date	( $-0.750 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-41.42
ATR14	$4.16 (2.85%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-20	Fitzgerald Kevin Joseph	Sell	0	Common Stock
2024-03-20	Fitzgerald Kevin Joseph	Buy	0	Common Stock
2021-02-11	Fitzgerald Kevin Joseph	Sell	9 000	Performance Stock Option 2017 (right to buy)
2024-03-20	Fitzgerald Kevin Joseph	Sell	16 250	Stock Option (right to buy)
2024-03-20	Fitzgerald Kevin Joseph	Sell	6 667	Stock Option (right to buy)

INSIDER POWER
-6.10
Last 99 transactions
Buy: 237 064 \| Sell: 275 392

Volume Correlation

Long: -0.65 (weak negative)

Short: -0.62 (weak negative)

Signal:(34) Neutral

Alnylam Pharmaceuticals Correlation

10 Most Positive Correlations
DSPC	0.92
AZTA	0.918
MAGS	0.917
RMRM	0.915
SLVO	0.914
EIGR	0.912
MMAC	0.906
VWE	0.905
ALVR	0.903
CVAC	0.903

10 Most Negative Correlations
MYNA	-0.939
MLTX	-0.916
NRDS	-0.914
HYPR	-0.912
EBSB	-0.911
FLXN	-0.911
UPTD	-0.906
NRC	-0.903
MNTV	-0.901
STRL	-0.898

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alnylam Pharmaceuticals Correlation - Currency/Commodity

-0.36
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.44
( neutral )

0.18
( neutral )

0.05
( neutral )

Alnylam Pharmaceuticals Financials

Annual	2023
Revenue:	$1.83B
Gross Profit:	$1.52B (83.02 %)
EPS:	$-3.52

Q4	2023
Revenue:	$439.72M
Gross Profit:	$353.86M (80.47 %)
EPS:	$-1.100

Q3	2023
Revenue:	$750.53M
Gross Profit:	$666.22M (88.77 %)
EPS:	$1.180

Q2	2023
Revenue:	$318.75M
Gross Profit:	$233.38M (73.22 %)
EPS:	$-2.21

Financial Reports:

No articles found.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.